GlassScriptPhysician profile
Liza A Moore
NPI 1730405010
$149,098.71
in general payments reported to CMS, 2019-2025
45 companies · $6,828 in 2025
The $6,828 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $25K · 2021: $11K · 2022: $15K · 2023: $8,825 · 2024: $21K · 2025: $6,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $8,936 · Consulting Fee: $5,850 · Travel and Lodging: $2,296 · Education: $110 · Gift: $33.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,400.00 |
| Food and Beverage | $8,936.46 |
| Consulting Fee | $5,850.00 |
| Travel and Lodging | $2,295.98 |
| Education | $110.12 |
| Gift | $33.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60,328.79 | 2019-2025 | |
| Celgene Corporation | $37,349.75 | 2019 | |
| Galderma Laboratories, L.P. | $18,959.78 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Amgen INC. | $11,475.63 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $10,097.19 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,226.35 | 2019-2025 | Dupixent |
| Incyte Corporation | $1,219.73 | 2021-2025 | Opzelura, Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $873.05 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Janssen Biotech, INC. | $776.64 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $747.28 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $665.05 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $573.92 | 2019-2025 | Winlevi, Absorica Ld |
| Journey Medical Corporation | $488.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $466.87 | 2019-2024 | |
| Dermavant Sciences, INC. | $464.50 | 2023-2024 | Vtama |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liza Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.